Gilead Symposium at HIV Glasgow 2024
Developed under the direction and sponsorship of Gilead Sciences, Inc. For healthcare professionals only.
At the HIV Glasgow 2024 congress, Gilead Sciences, Inc. hosted an interactive, patient case study-based symposium exploring emerging topics and patient-centred care for the clinical management of people with HIV.
The prescribing information for Gilead HIV medicines referenced on this page can be found below:
Click here for BIKTARVY®▼ (Bictegravir/emtricitabine/tenofovir alafenamide) United Kingdom prescribing information
Click here for BIKTARVY® (Bictegravir/emtricitabine/tenofovir alafenamide) Ireland summary of product characteristics
BIKTARVY® (Bictegravir/emtricitabine/tenofovir alafenamide) may not be prescribed in all countries. Please refer to your local prescribing information.
Adverse events should be reported. See the bottom of this page for all adverse event reporting information.
Our expert faculty panel explored person-centred treatment decisions, which are reflective of the diverse needs of individuals, and integral for helping people with HIV to achieve long-term success.
Session topics included:
- Rapid initiation of treatment
- The impact of ageing on HIV management
- Challenges related to adherence
- The importance of person-centred care
Hear more about this event from the meeting Chair, Sorana Segal‑Maurer:
Learn about the perspectives of Franco Maggiolo, Consultant, Fabro, Italy, on adherence challenges:
Listen to Fiona Bisshop, General Practitioner, Holdsworth House, Australia, discuss treatment optimisation in the presence of comorbidities:
Our international expert faculty panel
Sorana Segal-Maurer1
Franco Maggiolo2
Fiona Bisshop3
1. Sorana Segal-Maurer, Global HIV Medical Affairs, Gilead Sciences, USA
2. Franco Maggiolo, Consultant, Fabro, Italy
3. Fiona Bisshop, General Practitioner, Holdsworth House, Australia
This is a promotional page, as classified according to the ABPI Code of Practice, organised and funded by Gilead Sciences, Inc. This content is intended for healthcare professionals only and will involve discussions of Gilead products.
BIKTARVY®▼ is subject to additional monitoring in UK; this requirement no longer applies in Ireland. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
| Adverse events should be reported. For UK healthcare practitioners, reporting forms and information can be found at www.mhra.gov.uk/yellowcard/ or via the Yellow Card app (download from the Apple App Store or Google Play Store). For Ireland, reporting forms and information can be found at www.hpra.ie and can be reported to HPRA on +353 1 6764971. Adverse events should be reported to Gilead ([email protected]) or via https://www.gilead.com/utility/contact/report-an-adverse-event or +44 (0) 1223 897500. |
IHQ-PTF-0069 | January 2025
